Biomarin Pharmaceutical (NASDAQ:BMRN) will release its quarterly earnings report on Monday, 2025-08-04. Here’s a brief overview for investors ahead of the announcement.
Analysts anticipate Biomarin Pharmaceutical to report an earnings per share (EPS) of $0.93.
The market awaits Biomarin Pharmaceutical’s announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It’s important for new investors to understand that guidance can be a significant driver of stock prices.
Earnings History Snapshot
Last quarter the company beat EPS by $0.42, which was followed by a 1.08% drop in the share price the next day.
Here’s a look at Biomarin Pharmaceutical’s past performance and the resulting price change:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | 0.71 | 0.74 | 0.52 | 0.35 |
| EPS Actual | 1.13 | 0.92 | 0.91 | 0.96 |
| Price Change % | -1.0% | 5.0% | -5.0% | 8.0% |
Biomarin Pharmaceutical Share Price Analysis
Shares of Biomarin Pharmaceutical were trading at $57.85 as of July 31. Over the last 52-week period, shares are down 29.58%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.
Analyst Opinions on Biomarin Pharmaceutical
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Biomarin Pharmaceutical.
A total of 3 analyst ratings …